HomeAI · summaries
Storia in 10 fonti
Akeso, Summit drug extends survival in closely watched lung cancer trial
Ivonescimab reduced the risk of death by one-third compared to chemotherapy in a China-based study that’s seen as an important barometer for a class of cancer immunotherapies known as "PD-1/VEGF inhibitors."
Confronto fonti
6 prospettive sulla stessa storiaTimeline cronologica
- ·
biopharmadive.com
Akeso, Summit drug extends survival in closely watched lung cancer trial
Ivonescimab reduced the risk of death by one-third compared to chemotherapy in a China-based study that’s seen as an important barometer for a class of cancer immunotherapies…
- ·
statnews.com
Akeso and Summit’s ivonescimab extends survival in squamous cell lung cancer
A lung cancer drug developed in China was a highlight of ASCO but doctors want to see follow-up in a more diverse population.
- ·
fiercepharma.com
ASCO: Akeso’s ivonescimab bests PD-1 inhibitor in lung cancer chemo combos, slashing death risk by 34%
It’s the moment of truth for Akeso’s ivonescimab, and to many, a high-stakes test for China’s booming biotech industry. | Although the first-in-class PD-1xVEGF bispecific didn’t…
- ·
cnbc.com
A hotly debated lung cancer drug cut the risk of death by 34% in a late-stage trial in China
An experimental lung cancer drug from Akeso and Summit Therapeutics reduced the risk of death by 34% in a late-stage trial, according to data released Sunday.
- ·
endpoints.news
Summit, Akeso drug reduces death by 34% in China lung cancer study. Here’s what it means
The leading drug in biopharma's hottest immunotherapy race reduced the risk of death by 34% in previously untreated Chinese lung cancer patients, compared to standard…
- ·
independent.co.uk
New drug a ‘promising step forward’ for hard-to-treat lung cancer
Experts have described the findings as a ‘promising step forward‘ for patients with advanced squamous non-small cell lung cancer
- ·
morningstar.com
HARMONi-6 Demonstrates Significant Overall Survival Benefit (HR=0.66): Ivonescimab Plus Chemotherapy Superior to PD-1 Plus Chemotherapy in…
HARMONi-6 Demonstrates Significant Overall Survival Benefit (HR=0.66): Ivonescimab Plus Chemotherapy Superior to PD-1 Plus Chemotherapy in First-Line sq-NSCLC Landmark Results to…
- ·
Ivonescimab with Chemotherapy Demonstrated a Statistically Significant Overall Survival Benefit Compared to Tislelizumab Plus Chemotherapy…
Ivonescimab with Chemotherapy Demonstrated a Statistically Significant Overall Survival Benefit Compared to Tislelizumab Plus Chemotherapy in 1L Treatment of Patients with…
- ·
Newly developed drug helps extend the lives of lung cancer patients in trial
Stay up to date with notifications from The IndependentNotifications can be managed in browser preferences.Jump to contentThank you for registeringPlease refresh the page or…
- ·
medpagetoday.com
Upfront Ivonescimab Plus Chemo Bests PD-1 Inhibitor Combo in Advanced NSCLC
HARMONi-6 showed 34% drop in death risk, but trial had an all-Asian population, expert warned
- ·
2026 ASCO | Innovent Presents Long-Term Follow-up Results from the PoC Study of IBI363 (TAK-928) (PD-1/IL-2α-bias bispecific fusion…
2026 ASCO | Innovent Presents Long-Term Follow-up Results from the PoC Study of IBI363 (TAK-928) (PD-1/IL-2α-bias bispecific fusion protein), Showing Robust Survival Benefits in…
- ·
scmp.com
Akeso lung cancer drug trial raises hopes in US$20b market
Ivonescimab phase three trials reduce death risk by 34 per cent, as analysts predict it could transform non-small cell lung cancer therapy.
- ·
thenextweb.com
Akeso lung cancer drug cuts death risk 34% in landmark trial
Akeso's ivonescimab reduces death risk by 34% in phase three lung cancer trial, the first Chinese drug selected for ASCO's plenary in 61 years, targeting a $20B market.